Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn ...

(Yicai) Jan. 3 -- US pharmaceutical company Gilead Sciences has been given the greenlight by Chinese regulators to sell its ...

We came across a bullish thesis on Gilead Sciences, Inc. (NASDAQ:GILD) on Substack by Magnus Ofstad. In this article, we will ...

In 2023, the United States represented the largest portion of the Liver Fibrosis market, comprising around 79% of the total ...

Gilead Sciences has been a relatively solid performer this year in the biotech sector as its peers have struggled. The stock is up nearly 15% year-to-date, lagging the S&P 500. Yet it's rebounded 35% ...

Actor Mel Gibson recently opened up about a challenging chapter in his life, sharing details of his battle with COVID-19 and ...

A patent dispute between ViiV Healthcare and Gilead ... therapy, which could offset the decline, although it will face competition from other drugs including Pfizer's oral antiviral Paxlovid ...

This target product profile (TPP) highlights the minimal and optimal characteristics for ex-vivo and in-vivo cell and gene therapy-based products aimed ... SGD reports research support from Caring ...

in phase 3 trials as a potential therapy for people seriously ill with COVID-19, both alone and shortly in combination with Gilead Sciences’ antiviral remdesivir in the REMDACTA trial.

Gilead stock rated buy for thriving HIV biz, promising oncology pipeline, and long-term growth potential despite volatility.

The most recent trading session ended with Gilead Sciences (GILD) standing at $91.41, reflecting a -0.51% shift from the previouse trading day's closing. The stock's performance was behind the S&P ...